Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000221-20-AT (EUCTR)	23/10/2014	25/06/2014	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: RNS60 Product Code: RNS60	University Hospital Zürich	NULL	Not Recruiting			Female: yes Male: yes	16	Phase 2	Austria;Switzerland
2	NCT01714089 (ClinicalTrials.gov)	March 2013	19/10/2012	Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis	A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a	Revalesio Corporation	NULL	Withdrawn	18 Years	50 Years	Both	0	Phase 2	United States